UPCOMING DATA

Biotech Upcoming data

Quarter 4 2018

Ticker Phase Drug Notes Data Results
ACRS 2 ATI-502 data end of year
ALDX 3 Reproxalap Allergic conjunctivitis data end of quarter or 1Q '19
ALKS 3 ALKS 3831-ENLIGHTEN-2 Top-line results (fall)
AVEO 3 TIVO-3 due to slower enrollment, data is now in Q4
BHVN 2 Trigriluzole Top-line data
BLPH 3 INOvation-1 pulmonary arterial hypertension (PAH), with top-line data for the complete study anticipated around the end of the year
CMRX 2 CMX001 IV Brincidofovir for treatment of Viral infections
CMTA 3 MOVE trial evaluating palovarotene. Fibrodysplasia
FOMX 3 FX 2016-11 and FX2016-12 topical minocycline foam 1.5%, for the treatment of rosace. Top-line early fourth quarter.
GILD 2 GS-9674 Clinical data end of year. Liver diseases
GLPG 3 FINCH 2 Topline data 2H 2018
GTHX 2a trilaciclib triple-negative breast cancer. trilaciclib for patients undergoing chemotherapy, are expected in the fourth quarter of 2018.
GTXI 2 ASTRID Top-line result expected early Q4
KPTI 2b SADAL for the treatment of patients with relapsed or refractory DLBCL
KURA 2 Tipifarnib data from multiples phase 2 tipifarnib in solid tumor and hematologic
MNLO 2 Seropitant Data in Refractory Chronic Cough Expected in Oct 2018.
MRNS 2 Intravenous (IV) ganaxolone Report top-line P2 Magnolia study in women with PPD
MRNS 2 MAGNOLIA Report top-line oral ganaxolone data from Amaryllis study in women with moderate PPD fourth quarter 2018
NOVN 2 SB206 Viral infections data
OBSV 3 IMPLANT 2 Clinical trial of nolasiban in IVF. Also P2a PRLONG Safety, tolerability and pharmacokinetics in pregnant women, and interim efficacy .
OPHT 2a Zimura In April 2018, complete patients enrollments. Evaluate data at six months.
PBYI 2 CONTROL Top-line data
PRTO 3 PATENCY-2 data Q1 '19 and possibly late '18
PULM 2a PUR1800 for COPD
SBBP 3 COR-003-LOGICS Topline data
SRRA I/II SRA737 Interim data
SYBX 1b/2a SYNB1020 In development for the treatment hyperammonemia. Data end of 18
SYRS 2 SY-1425 Expect to Report Initial Data from Combination Arms
TCON 3 TRC105 interim analysis from the Phase 3 pivotal TAPPAS trial of TRC105 in angiosarcoma is expected in the second half of 2018.
UTHR 3 FREEDOM-EV clinical data
VKTX 2 VK2809 data from P2 fatty liver and hypercholesterolemia data 2H 2018
VNDA 2 Tradipitant for gastroparesis (gastroenterology) data end of year.
VTVT 3 STEADYFAST- Part B data late 2018
XNCR 2 XmAb®5871 Systemic Lupus Erythematosus (SLE).

Quarter 3 2018

Ticker Phase Drug Notes Data Results
ALDX 2 and 3 Reproxalap Ocular Phase 3 Allergic Conjunctivitis , P2b Dry Eye Disease, P3 Noninfectious Anterior Uveitis and P3 sjogren-Larsson Syndrome. All expected second half 2018
ALNY 3 ENVISION interim analysis mid-2018. Givosiran (Acute Hepatic Porphyrias)
AMRN 3 REDUCE-IT Topline results expected to be available before the end of Q3 2018
ANAB 2a ANB020 in Eosinophilic Asthma Expected in the Third Quarter of 2018
ARGS 2 AGS-004 interim data due 2h 2018
ARNA 2 Olorinab study in pain associated with Crohn's disease
ATNX 3 Oraxol KX-ORAX-001 second inerim analysis in 3Q 2018
ATXI 3 IV tramadol for management of moderate to moderately severe postoperative pain in patients following bunionectomy surgery.
AXON 2 Nelotanserin REM Behavior Disorder in subjects with LBD
AXSM 2 AXS-05 ASCEND study for major depressive disorder (MDD). Top-line results 2H '18
BLPH 3 PAH INOvation-1 The company continues to expect the readout of interim analyst in mid-2018. DMC recommends stopping Phase 3.
BYSI 3 Piabulin Interim P3 mid-2018
CANF 2 Namodenoson Namodenoson in the treatment of heaptacellular carcinoma (HCC) expected later in 2018
CTIC 3 PIX306 trial of PIXUVRI, top-line results are expected 2Q PIXUVRI did not meet endpoint
EIGR 2 Exendin 9-39 IN PBH Exedin 9-39 phase 2 PREVENT study, and Ubenimex in Lymphedema; phase 2 ULTRA study completion.
ENTX 2 PTH (1-34) and NatPar Complete the first part of Phase 2 in Aug 1, data in coming months. Hypoparathyroidism
ESPR 3 Bempedoic Acid Global pivotal P3 study 2 52 weeks LDL-C
FLKS 2b COMMEND trial FLXS-787 Topline 3q 2018 Discontinue trial
GALT 2 KEYTRUDA enroll cohort 3 (GR-MD-02 8 mg/kg) of the pembrolizumab (KEYTRUDA) combination immunotherapy clinical trial, data mid-2018
IONS 2 AKCEA-APO(a)-LRx and AKCEA-ANGPTL3-LRx six Phase 2 programs throughout 2018
OBSV 2B OBE2109 due mid 2018
OCUL 3 OTX-TP Expects topline efficacy data 2h 2018
OMER 2 OMS721 Immunoglobulin A (IgA) nephropathy.
ONCE I/II Hemophila A- SPK-8011 investigational gene therapy
ONCS 2b PISCES/KEYNOTE-695 Dosing of first patient on Dec 14, 2017. data in 2018. (No specific quarter given)
OVID 2 OV101- STARS Enrollment i n STARS trial to adolescent Angelman syndrome. Trial to be available 2H 2018 Positive data, but investors concerned stock -36.55% for the day.
PBYI 3 PB272 (neratinib) third-line metastatic breast cancer patients in the second half of 2018
RARE 2 Crysvita (burosumab) his is an open label Phase 2 study evaluating the safety and efficacy of burosumab in 17 adult patients with TIO.
RDHL 3 RHB-104 Topline data Primary endpoint successfully achieved.
SCYX 2b SCY-078 Topline data by July positive results oral SCY-078
SPPI 2 Poziotinib Breast Cancer. Data possibly release in fall
TGTX 3 UNITY-CLC Top-line ORR and relapsed/refractory Chronic Lymphocytic Leukemia (CLL).
TNXP 3 HONOR study of Tonmya Interim Analysis 3Q 2018;Topline results expected in 3Q 2018 discontinue Phase 3 HONOR
TOCA 3 TOCA 5 conducting 50% interim analysis 2H '18
TORC 2b TORC1 top-line 16 weeks data expected 3Q. trial is designed to evaluate the safety, tolerability and efficacy of RTB101, an orally-administered selective TORC1 inhibitor, announces 'positive' P2b RTB101
URGN 3 OLYMPUS topline data
ZGNX 3 ZX008 Second pivotal trial Phase 3 Dravet syndrome program, STUDY 1504. Data late June-early July. Primary endpoint achieved

Quarter 2 2018

Ticker Phase Drug Notes Data Results
ACRS 2 AT-50002 Topical Top-line data 1H 2018 positive interim data
ALXN 3 PREVENT and ALXN210 Data mid-2018. Eculizumab- Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Success
AQXP 3 AQX-1125 LEADERSHIP data Failed to meet primary endpoint
AXSM 3 STRIDE-1 trial of AXS-05 IN TRD, top-line data 1H 2018
BMRN 2 Hemophilia A update on the ongoing Phase 2 program with valoctocogene roxaparvovec at the World Federation of Hemophilia 2018 World Congress. May 20-24 Data were updated at World Congress
CARA 3 CR845 Acute Post-Operative Pain, data expected in 2Q Report 'positive' topline data
CLDX 2b METRIC Topline data likely Q2 2018 Data failed
CLSD 2 TYBEE Patients follow-up six months data -32.19% Stock reaction to 'positive' data.
EDGE 3 EG-1962 Interim-topline data data failed
ESPR 3 ASCVD and/or HeFH Statin add on Global pivotal P3 study 1, 52 weeks long term safety. Company press 'positive' data, but safety concerns dropped stock -35.11%.
FOMX 3 FMX103 Topline data mid 2018
GBT 3 HOPE study Top -line clinical data by end of quarter Primary endpoint achieved
GEMP 2B INDIGO-1 Top-line data Meet primary endpoint
GLMD 2b ARREST Phase IIB data late Q1 or early Q2 2018. Data update stock up +151.29%
GNMX 2 AEVI-001 Phase 2 (ASCEND) for patients with ADHD. Data expected mid-2018
HRTX 2 HTX-011 data likely late Q2 for kneee arthroplasty positive topline results. Stock up +30.13%
IDRA 2 IMO-8400 Topline data in June miss primary endpoint
INCY 3 ECHO-301 Initial results of the ECHO-301 trial of epacadostat in melanoma and REACH 1 trial of ruxolittinib in acute GVHD Data failed
IONS P1/2a IONIS-SOD1 ALS Topline Data Mid Q2
JNCE 1/2 ICONIC Preliminary Efficacy data in the first half of 2018 Underwhelming abstract, stock -35.20% reaction
KPTI 2 STORM April data Positive Phase 2a
MDGL 2 MGL-3196 Final 36-week data, top line results by end of May MDGL-3196 Achieves Endpoints
MNLO 2 ATOMIK atopic dermatitis data expected April 2018 Data failed
NBRV 3 LEAP 2 Data are expecting in Spring 2018 Company press lefamulin meets all primary endpoints. Stock down -16.57%
PRTA IIb NEOD1 Top-line data Data failed, stock down -68.78%
SBBP 3 RECORLEV Top-line results on track with SONICS Positive results.
SELB 2 SEL-212 Symtomatic Gout Patients. Updated Clinical data at PANLAR Congress on Tuesday, April 10, 2018
VICL 2 HSV-2 Therapeutic Vaccine trial vaccine did not meet primary endpoint
VTVT 3 STEADFAST STEADFAST study (azeliragon in Alzheimer's disease) Part A early 2018 Data failed
XLRN 3 MEDALIST and BELIEVE Data mid 2018 Achieved primary and secondary endpoints

Quarter 1 2018

Ticker Phase Drug Notes Data Results
ACOR 3 Tozadenant Phase 3 data
AIMT 3 PALISADE "Anticipate sharing topline in first quarter 2018"
ANAB 2 ANB020 Phase 2 data readout in adult severe peanut allergy.
ANTH 3 Sollpura-RESULT data due end of Q1
ARGX 2 ARGX-113 Myasthenia gravis data
AXON 2 Intepirdine and Nelotanserin January data: HEADWAY in patients with dementia with Levy bodies (DLB). subjects with Alzheimer's disease, DLB and Parkinson's disease dementia (PDD). Nelotanserin (LBD).
AXSM 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis
BHVN 3 RIMEGEPANT Top-line results
BLPH 3 INO pulse for PAH indication Topline line data
BOLD 1/2 AT132 Phase 1/2 data readout of AT132 XLMTM
CDTX 2 STRIVE CD101 IV
Cidara Therapeutics Inc (CDTX) 2 STRIVE completing enrollment of the 90-patietn. P2 Rezafungin
CLSD 3 PEACHTREE Macular Edema Associated with Non-infectious Uveitis, top line data.
CPRX 2 CMS-001 Expect top-line results from CMS-001 in first half 2018
DERM 3 CLAREOS 1 and CLAREOS 2 October 5, 2017 completes patient enrollment in Two Phase 3 pivotal trials of Olumacostat Glasaretil for the treament of Acne Vulgaris. Topline.
EARS 3 KEYZILEN P3 TACTT3 topline data
EIGR 2 LIBERTY Ubenimex in PAH
EYEG 3 EGP-437 Topline data
FGEN 2 FG-3019 Pancreatic caner study results
FLKS 2 FLX-787 Multiples Sclerosis Readout data end of Q1
GEMP 2b INDIGO-1 top-line data
GTHX 2a trilaciclib trilaciclib first-in-line small cell lung cancer. Data in March
IDRA 2 IMO-2125 Clinical trial of 8mg intratumoral IMO-2125 in combination with ipilimumab in anti-PD1 reffractory melanoma. ORR data
MNOV 2 mn-166 Completion enrollment news on Sept 19,2017. Final data Q1
MRNS 2 CDKL5 on-going in the Magnolia Study, with data expected in early 2018
OVID 2 STARS Sometimes 2018
PTGX 2b PTG-300 interim analysis early 2018
REGN 3 Praluent ODYSSEY OUTCOMES Cardiovascular events.
TCON 2 TRAXAR trial of TRC105 Top-line data from the randomized P2
TRPX IIa THX-110 Tourette syndrome. Top-line anticipated in first half 2018
TTPH 3 IGNITE3 Additional data
VBLT 3 VB-111 top-line results
VICL 3 ASP0013 The multinational phase 3 registration trial in HCT recipients completed enrollment in Sept 2016 with a total 515 subjects.
VRTX 2 VX-445 and VX-659 triple combinations in CF patietns data 1H18
VTGN 2 AV-101 P2 monotherapy study completion expected early 2018
VTVT 3 STEADFAST STEADFAST study (azeliragon in Alzheimer's disease) Part A early 2018 Data failed

Quarter 4 2017

Ticker Phase Drug Notes Data Results
ADRO 2 CRS-207 in combination with pembrolizumab Report early observations from the ongoing phase 2 mesothelioma study
AGLE 1 AEB1102 Potential data end of year.
ANAB 2a ANB020 Multiple Top-Line Clinical data readouts expected in second half of 2017
ARDX 3 T3MPO-2 Results of Tenapanor for IIBS-C on track early Q4
AVXL 2a ANAVEX 2-73 PK/PD data
CALA 2 CB-839 In July 2017, Calithera initiated a phase 2 trial of CB-839 with pcitaxel in triple negative breast cancer patietns.
CLDX 2 Glembatumumab Vedotin The company anticipated in fall of 2017
CNCE 2b CTP-543 End of year data
CPRX 3 Firdapse® Top-line Results expected in early December. Completes enrollment in second phase 3 trial on Oct 31,2017
CYTK 3 VITALITY-ALS Trial of Tirasemtiv
DBVT 3 PEPITES to report topline results from PEPITES in October 2017
EARS 3 AM-111 HEALOS The trial enrolled 256 patients with severe to profound idiopathic sudden sensorineural hearing loss.
EIGR 2 LIMT HDV interim data study at AASLD
GALT 2b NASH-CX Clinical data in December
IRWD 2 IW-1973 data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017.
KDMN 2 KD025 Randomized, open-label clinical trial in idiopathic pulmonary fibrosis
KDMN 2 KD025 Randomized, open-label clinical trial in idiopathic pulmonary fibrosis and full data to severe psoriasis
KURA 2 tipifarnib Phase 2 trial of tipifarnib in HRAS mutant SCCHN second half 2017
MDGL 2 MGL-3196 for NASH Top-line results for the primary endpoint of the trial, the reduction of liver fat, assessed by MRI-PDFF at 12 weeks, are expected by year-end
MLNT 2/3 Taksta exploratory trial data in refractory bone and joint infections.
MNOV 2b SPRINT-MS/NN 102 phase 2b Trial of Ibudilast in progressive MS has been accepted for oral platform presentation at 7th Join ECTRIMS*ACTRIMS meeting October 25-28, 2017 in Paris, France
ONTX 3 INSPIRE interim analysis anticipate in Q4
RARX 2 RA101495 Cohort B of Ra Pharma's Phase 2. The company remains on track to report additional data around year-end.
RVNC 2 RT002 RT002 injectable in management of plantar fascitis
RVNC 3 SAKURA 1&2 rt002 Injectable for the treatment of glabellar (frown) lines
SAGE 2 SAGE-217 SAGE-217 in PPD and essential tumor 2H2017
SGEN 3 ADCETRIS Full data from ADCETRIS phase 3 ECHELON-1 trial
STML 2 SL-401 In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Top line results in 2h17
SYRS 2 SY-1425 on track to present initial phase 2 clinical data
TGTX 2 TG-1101 multiples sclerosis trial update
VKTX 2 VK5211 Phase 2 hip fractured study full enrolled, data expected Q4 '17. From Aug 19 press released

Quarter 3 2017

Ticker Phase Drug Notes Data Results
ABBV 3 SELECT-BEYOND top-line data likely 3Q
ABUS 2 HBV ARB1467 data
ABUS 2 ARB-1467 top-line results from the three-month bi-weekly dosing expect to be announced in September
ALDX 2A ADX-102 Clinical trial in Dry Eye Disease
ALNY 2 hempohillia Fitusiran PII OLE dadta
ALNY 3 APOLLO results for Patisiran in near term
ANAB 2a ANB020 Multiple Top-Line Clinical data Readouts expected in Second half of 2017
ANTH 2 BRIGHT BRIGHT study of blisibimod in IgA
ARRY 3 BEACON CRC data from the safety due at ESMO
AXON 3 Alzheimer's disease Data to be out in September 2017
AZRX IIa MS1819 expect completion Phase IIa in 3Q
BLPH 2a PH-IPF "results of this study in near futture" -Mr. Tenenbaum
FOLD 3 SD-101 SD-101 for Epidermolysis Bullosa (EB), Top-line P3 late 3Q
GILD 2 GS-0976 NASH data
GTXI 2 Enobosarm top-line results in 3Q
INSM 3 ARIKAYCE data out in September
KDMN 2 KD025 Open-label, dose finding clinical trial in chronic graft-versus-host disease. Also Tesevatinib data
MDCO 3 Meropenem-Vaborbactam TANGO 2 end of 3Q
MRNS 2 CDKL5 Phase 2 trial evaluating children with CDKL5 disorder
MRTX 2 NSCLL AMETHYST trial
NBRV 3 Infections LEAP 1 data.
OTIC 3 AVERTS-1 Phase 3 AVERTS-1 trial for OTIVDEX(tm) in September
RDHL 2 BEKINDA IBS-D data in September
SAGE 3 Brexanolone in SRSE top-line results from STATUS trial
STML 2 SL-401 top-line results in 2h17
VNDA 2 Tradipitant study for treatment of chronic pruritus in patients with atopic dermatitis.
VSAR 3 Pediatric GHD Top line from pediatric phase 3 Velocity trial around end of September
VSTM 3 Duvelisib Phase 3 DUO top-line latter part of summer
ZYNE 2 FAB-C top-line results from the FAB-C Fragile X study in September

Quarter 4 20018

Ticker Phase Drug Notes Data Results
FGEN 3 Roxadustat topline data for anemia in chronic kidney disease

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.